MX2022006574A - Uso de un anticuerpo anti-factor xii para el tratamiento o la prevencion del angioedema hereditario. - Google Patents

Uso de un anticuerpo anti-factor xii para el tratamiento o la prevencion del angioedema hereditario.

Info

Publication number
MX2022006574A
MX2022006574A MX2022006574A MX2022006574A MX2022006574A MX 2022006574 A MX2022006574 A MX 2022006574A MX 2022006574 A MX2022006574 A MX 2022006574A MX 2022006574 A MX2022006574 A MX 2022006574A MX 2022006574 A MX2022006574 A MX 2022006574A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
hereditary angioedema
factor xii
antibody
Prior art date
Application number
MX2022006574A
Other languages
English (en)
Inventor
Ying Zhang
Ingo Pragst
Dipti Pawaskar
Theresa Yuraszeck
Original Assignee
CSL Innovation Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Innovation Pty Ltd filed Critical CSL Innovation Pty Ltd
Publication of MX2022006574A publication Critical patent/MX2022006574A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un anticuerpo anti-FXII para usarse en un método para tratar o prevenir el angioedema hereditario (HAE) en un sujeto, en donde el anticuerpo se administra por vía subcutánea al sujeto.
MX2022006574A 2019-12-03 2020-12-03 Uso de un anticuerpo anti-factor xii para el tratamiento o la prevencion del angioedema hereditario. MX2022006574A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962943117P 2019-12-03 2019-12-03
US202063093975P 2020-10-20 2020-10-20
PCT/AU2020/051321 WO2021108862A1 (en) 2019-12-03 2020-12-03 Use of an anti-factor xii antibody for the treatment or prevention of hereditary angioedema

Publications (1)

Publication Number Publication Date
MX2022006574A true MX2022006574A (es) 2022-07-19

Family

ID=76220899

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006574A MX2022006574A (es) 2019-12-03 2020-12-03 Uso de un anticuerpo anti-factor xii para el tratamiento o la prevencion del angioedema hereditario.

Country Status (10)

Country Link
US (1) US20230002508A1 (es)
EP (1) EP4069750A4 (es)
JP (1) JP2023506403A (es)
KR (1) KR20220109451A (es)
CN (1) CN114761437A (es)
AU (1) AU2020396054A1 (es)
CA (1) CA3159675A1 (es)
IL (1) IL293512A (es)
MX (1) MX2022006574A (es)
WO (1) WO2021108862A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102042982B1 (ko) * 2011-07-22 2019-11-11 체에스엘 베링 게엠베하 억제성 항-ｘｉｉ/ｘｉｉａ 인자 모노클로날 항체 및 이들의 사용
CA2916399C (en) * 2013-06-28 2022-08-02 Marc Nolte Combination therapy using a factor xii inhibitor and a c1-inhibitor
EP3325516B1 (en) * 2015-07-21 2021-12-15 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor xiia
WO2017173494A1 (en) * 2016-04-06 2017-10-12 Csl Limited Method of treating atherosclerosis
CN111479587B (zh) * 2017-12-15 2024-01-09 杰特有限公司 FXIIa抑制剂在治疗肾纤维化和/或慢性肾脏疾病中的应用
EP3983448A4 (en) * 2019-06-12 2023-11-22 CSL Innovation Pty Ltd SOLUBLE COMPLEMENT RECEPTOR TYPE 1 VARIANT CONJUGATES AND RELATED USES

Also Published As

Publication number Publication date
KR20220109451A (ko) 2022-08-04
EP4069750A1 (en) 2022-10-12
IL293512A (en) 2022-08-01
CN114761437A (zh) 2022-07-15
EP4069750A4 (en) 2023-12-20
AU2020396054A1 (en) 2022-07-07
WO2021108862A1 (en) 2021-06-10
CA3159675A1 (en) 2021-06-10
US20230002508A1 (en) 2023-01-05
JP2023506403A (ja) 2023-02-16

Similar Documents

Publication Publication Date Title
MX2022002977A (es) Tratamiento y prevencion del cancer usando moleculas de union a antigeno her3.
AU2018238202A8 (en) Combination therapy for the treatment or prevention of tumours
EP4316517A3 (en) Combination therapy against cancer
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
AU2016255707A8 (en) Uses of cannabidiol for treatment of infantile spasms
RU2010133480A (ru) Лечение метастатической стадии рака предстательной железы дегареликсом
MX2021014557A (es) Tratamientos de angioedema hereditario.
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MX2018008855A (es) Composicion que comprende toxina botulinica.
BR112021014699A2 (pt) Métodos de tratamento de mieloma múltiplo
WO2020047352A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
MX2021014558A (es) Tratamientos de angioedema.
BR112022005757A2 (pt) Uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
MX2022002751A (es) Tratamiento de la abstinencia de opioides.
MX2021011230A (es) Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades.
MX2022010258A (es) Composiciones y métodos para tratar la lesión renal.
WO2019139956A3 (en) Prevention and treatment of organ fibrosis
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
MX2022006574A (es) Uso de un anticuerpo anti-factor xii para el tratamiento o la prevencion del angioedema hereditario.
MX2023005563A (es) Profilaxis y tratamiento del angioedema.
MX2022000783A (es) Inhibidores de la ferroportina para el uso en la prevencion y el tratamiento de lesiones renales.
MX2022011845A (es) Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).